10-Q: Pasithea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Update

Pasithea Therapeutics reported a net loss of $2.99 million for the third quarter of 2024, while also providing updates on their clinical trial for PAS-004 and a recent capital raise.

Summary

• Pasithea Therapeutics reported a net loss of $2.99 million for the three months ended September 30, 2024, compared to a net loss of $3.61 million for the same period in 2023.
• The company's operating expenses were $3.0 million for the quarter, with $1.42 million in general and administrative costs and $1.58 million in research and development expenses.
• For the nine months ended September 30, 2024, the net loss was $10.73 million, compared to $10.91 million for the same period in 2023.
• The company's cash and cash equivalents were $9.36 million as of September 30, 2024, down from $16.33 million at the end of 2023.
• Pasithea completed a private placement in September 2024, raising approximately $4.5 million in net proceeds.
• The company is currently conducting a Phase 1 clinical trial for PAS-004, with plans to open additional sites in Eastern Europe in the fourth quarter of 2024.
• The company has discontinued its clinics segment and is now focused on its therapeutics segment.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical trial and a successful capital raise, the company's financial position is weak, with significant losses and a need for further funding. The material weakness in internal controls also adds a negative aspect.

Positives

• The net loss for the third quarter of 2024 was lower than the same period in 2023, indicating improved financial performance.
• The company successfully raised $4.5 million through a private placement, strengthening its financial position.
• The Phase 1 clinical trial for PAS-004 is progressing, with plans for expansion to new sites.
• The company has completed long-term chronic toxicity studies for PAS-004, a key step in drug development.
• The appointment of Dr. Rebecca Brown to the Scientific Advisory Board adds expertise in neurofibromatosis.

Negatives

• The company continues to experience significant operating losses and negative cash flows.
• Cash and cash equivalents decreased from $16.33 million at the end of 2023 to $9.36 million as of September 30, 2024.
• The company's working capital decreased by approximately $5.0 million between December 31, 2023 and September 30, 2024.
• Management believes that the company will not have sufficient working capital to meet its needs through twelve months from the issuance date of the financial statements without raising additional capital.
• The company has identified a material weakness in its internal controls related to the review of the annual income tax provision.

Risks

• The company has a limited operating history and expects to incur significant operating losses for the foreseeable future.
• The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities.
• The development and commercialization of product candidates is a lengthy and expensive process with an uncertain outcome.
• The company is dependent on third parties for various aspects of its operations, including manufacturing and clinical trials.
• The company's reliance on foreign contract research organizations (CROs) and contract manufacturing organizations (CMOs) may be subject to U.S. legislation, trade restrictions and other foreign regulatory requirements.
• The company's financial performance and ability to sustain an active trading market for its stock and warrants are subject to various risks.
• The company's operations could be disrupted by public health crises, global economic conditions, and geopolitical events.

Future Outlook

The company expects to continue to incur significant expenses and operating losses as it advances its product candidates through development and clinical trials. They are dependent on raising additional capital to continue operations and execute their development plans. The company plans to open additional clinical trial sites in Eastern Europe in the fourth quarter of 2024.

Management Comments

• Management believes that the company will not have sufficient working capital to meet its needs through twelve months from the issuance date of the condensed consolidated financial statements, without raising additional capital.
• Management believes that the company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.

Industry Context

Pasithea is operating in the competitive biotechnology sector, focusing on treatments for central nervous system disorders and RASopathies. The company's focus on PAS-004, a MEK inhibitor, places it in a space with other companies developing targeted therapies for similar conditions. The company's decision to discontinue its clinics segment and focus on therapeutics is a strategic move to concentrate resources on its core drug development programs.

Comparison to Industry Standards

• Pasithea's cash burn rate is typical for a clinical-stage biotech company, but the need for additional capital raises is a common challenge in the industry.
• The company's focus on a Phase 1 clinical trial for PAS-004 is consistent with the development timelines of other early-stage biotech firms.
• The decision to discontinue the clinics segment is similar to other companies that have streamlined operations to focus on core research and development activities.
• The company's reliance on third-party CROs and CMOs is a standard practice in the biotech industry, but it also introduces risks related to supply chain and regulatory compliance.
• The company's financial results are comparable to other small-cap biotech companies in the early stages of clinical development, with significant operating losses and a reliance on external funding.

Management Changes

Related Party Transactions

• The company made payments to PsychoGenics, Inc., where a board member is the CEO, for preclinical studies.
• The company has a consulting agreement with Prof. Lawrence Steinman, who receives $25,000 per quarter for his services.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, stock price, and the need for additional capital raises.
• Employees are impacted by the company's financial stability and the ongoing research and development activities.
• Customers (potential patients) are impacted by the progress of the company's clinical trials and the potential for new treatments.
• Suppliers and creditors are impacted by the company's ability to meet its financial obligations.

Next Steps

• The company plans to open additional clinical trial sites in Eastern Europe in the fourth quarter of 2024.
• The company intends to use the net proceeds from the September 2024 private placement for working capital and general corporate purposes.
• The company will continue to develop PAS-004 and other product candidates.

Key Dates

Keywords

biotechnology, therapeutics, clinical trial, PAS-004, MEK inhibitor, RASopathies, neurofibromatosis, capital raise, financial results, research and development